Psychiatric NP Scope of Practice for ADHD

You’ve built your psychiatric practice around treating ADHD — or you’re considering it — and telehealth seems like the obvious solution to reach more patients while maintaining work-life balance. But then you hit the regulatory wall: Can I legally prescribe Adderall through a video visit? What about Vyvanse or Ritalin? Does it matter which state my patient is in?

If you’ve searched ‘telehealth prescribing ADHD meds’ or ‘DEA rules stimulants telemedicine,’ you’ve probably found conflicting answers from 2020, vague summaries, or lawyer-speak that doesn’t tell you what you actually need to know.

Here’s the reality: Yes, you can prescribe ADHD medications via telehealth in 2026 — but the rules are temporary, vary by state, and depend heavily on your provider type. A psychiatrist in California faces different requirements than a PMHNP in Texas or Florida. And with the DEA planning permanent regulations by 2027, understanding both current flexibilities and what’s coming is critical for building a sustainable telehealth practice.

This guide cuts through the confusion with actual regulations, state-by-state breakdowns for our six priority markets (California, Texas, Florida, New York, Pennsylvania, Illinois), and what it means for your practice economics.

The Federal Framework: Where We Stand Through 2026

The Ryan Haight Act: The Rule That Started It All

Before COVID-19, the Ryan Haight Online Pharmacy Consumer Protection Act made prescribing controlled substances via telehealth nearly impossible. The law required at least one in-person medical evaluation before any practitioner could prescribe a controlled substance like Adderall or Ritalin. The DEA had theorized about a ‘special registration’ pathway for telemedicine prescribing but never implemented it.

For ADHD-focused providers, this meant telehealth was limited to therapy and follow-ups — initial medication starts required patients to come to a physical office.

COVID Changed Everything (Temporarily)

In March 2020, the DEA used emergency authority to waive the in-person exam requirement for Schedule II-V controlled substances. Suddenly, psychiatrists and PMHNPs could initiate stimulant treatment via video visits without ever seeing a patient face-to-face, as long as the prescription was legitimate and issued through a real-time audio-visual consultation.

This flexibility was supposed to end when the Public Health Emergency ended in May 2023. But recognizing how many patients now depended on telehealth ADHD care, the DEA has extended the waiver four times.

Current Status: Extended Through December 31, 2026

As of January 2026, the DEA and HHS announced the fourth extension of telemedicine flexibilities through the end of 2026. This means:

• You can prescribe Schedule II stimulants (Adderall, Vyvanse, Ritalin, Concerta) via telehealth without any initial in-person visit
• The evaluation must be via live video (not just phone or questionnaire)
• All standard prescribing requirements still apply: legitimate medical purpose, proper diagnosis, checking your state’s PDMP, using electronic prescribing
• State licensure matters: You must be licensed in the patient’s state

This isn’t permanent. It’s a stopgap while the DEA finalizes new rules — which brings us to what’s coming.

What the DEA’s Permanent Rules Will Likely Require

The DEA has previewed three new telemedicine rules (announced January 2025, expected to be finalized by late 2026 or early 2027):

1. Telemedicine Special Registration
Providers will be able to obtain a special DEA registration authorizing them to prescribe controlled substances via telehealth without an in-person exam. The catch: you’ll need to comply with enhanced safeguards, including mandatory nationwide PDMP checks and strict patient identity verification.

2. Established Patient Exception
If you’ve seen a patient in person at least once (or they’ve been seen by someone in your practice group), the telehealth rules won’t apply — you can continue prescribing freely via video.

3. Platform Registration
For the first time, telehealth platforms that facilitate controlled substance prescribing will need to register with the DEA. This adds corporate-level oversight to prevent ‘pill mill’ operations.

The proposed rules are designed to balance access with safety. They’ll likely allow ongoing ADHD treatment via telehealth but with more structure than the current blanket waiver.

Bottom line for your practice planning: Through 2026, operate under current flexibilities. But if you’re building a telehealth-heavy ADHD practice, expect to obtain the special registration in 2027 and budget for enhanced compliance (PDMP checks, documentation standards, platform fees if applicable).

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-by-State Rules: Where It Gets Complicated

Federal law sets the floor, but states can add requirements — and they do. Here’s what you need to know for each priority state.

California: Telehealth-Friendly, NPs Gaining Independence

Telehealth Prescribing Rules:
California doesn’t require an in-person exam beyond federal requirements. State law explicitly allows telehealth evaluations to satisfy prescribing standards — you can even use structured online questionnaires combined with video follow-up if clinically appropriate.

There’s no California-specific ban on prescribing Schedule II controlled substances through telemedicine. You just need to meet the standard of care.

Key Requirements:

• PDMP: You must check the CURES database (California’s PDMP) before the initial prescription and at least every 4 months for ongoing Schedule II therapy
• E-Prescribing: Required for controlled substances
• Informed Consent: Document telehealth consent (recommended, not strictly mandated)

Licensure:
You must hold a California license. CA is not part of the Interstate Medical Licensure Compact (IMLC), so out-of-state physicians need a full license — which can take 3-6 months to obtain.

NP Scope of Practice:
California is transitioning to full practice authority for nurse practitioners. As of 2023, NPs with 3 years or 4,600 hours of supervised practice can become independently licensed. By 2026, experienced PMHNPs will be able to prescribe ADHD medications without physician oversight.

New-grad NPs still need supervising agreements initially, but the trend is clear: California is opening up NP independence, which will expand the pool of ADHD prescribers.

Practice Implications:
California’s large population and telehealth-friendly regulations make it an attractive market, but getting licensed takes time. If you’re not already CA-licensed, plan accordingly.

Texas: Physicians Only for Stimulants

Telehealth Prescribing Rules:
Texas permits telemedicine for mental health treatment. There’s a law prohibiting telehealth prescribing of controlled substances for chronic pain, but ADHD doesn’t fall under that restriction.

Psychiatrists (MD/DO) can prescribe stimulants via telehealth following federal rules — video evaluation, standard of care, documentation.

The NP Problem:
Here’s where Texas gets restrictive. Nurse practitioners and physician assistants cannot prescribe Schedule II controlled substances in outpatient settings — period. The only exceptions are inpatient hospital orders (for patients hospitalized ≥24 hours), hospice care, or emergency department orders.

Outpatient ADHD treatment doesn’t qualify. This means:

• PMHNPs cannot prescribe Adderall, Vyvanse, or Ritalin to Texas patients, even with physician collaboration
• Only physicians (MD/DO) can write these prescriptions

If you’re a PMHNP wanting to treat ADHD patients in Texas via telehealth, you’ll need a physician collaborator to actually sign the prescriptions. On a platform like Klarity, this would require physician oversight or limiting your TX practice to non-controlled medications (like Strattera or Wellbutrin for ADHD, which NPs can prescribe).

Key Requirements:

• PDMP: Texas mandates PMP checks for opioids, benzos, barbiturates, and carisoprodol — stimulants aren’t on the mandatory list, but checking is best practice
• E-Prescribing: Mandatory for all controlled substances in Texas (as of 2021)
• Licensure: Texas is part of IMLC for physicians; NPs need full TX licensure

Practice Implications:
If you’re a psychiatrist, Texas is wide open for telehealth ADHD care. If you’re a PMHNP, you’re essentially locked out of stimulant prescribing unless you partner with a physician — which affects your earning potential and autonomy.

For telehealth platforms, this means Texas requires a physician-heavy provider network for ADHD medication management.

Florida: Clear Exception for Psychiatric Treatment

Telehealth Prescribing Rules:
Florida has one of the clearest telehealth laws for our purposes. State statute explicitly prohibits prescribing Schedule II controlled substances via telehealth except for:

1. Treatment of a psychiatric disorder
2. Inpatient hospital care
3. Hospice care
4. Nursing home residents

Since ADHD is a psychiatric disorder, you’re explicitly allowed to prescribe stimulants via telehealth in Florida. This carve-out was built into the law when Florida established telehealth rules in 2019.

Key Requirements:

• PDMP: Must check E-FORCSE (Florida’s PDMP) before prescribing controlled substances to patients age 16+
• Out-of-State Provider Registration: Florida offers a telehealth registration for out-of-state providers — you can treat Florida patients without getting a full FL license, as long as you hold an active, unrestricted license in another state and meet other criteria
• Standard of Care: The psychiatric disorder exception doesn’t lower the bar — you still need a proper ADHD evaluation, just via video

NP Scope of Practice:
Florida’s rules are nuanced:

• Psychiatric Nurse Practitioners (defined as APRNs with an advanced degree in psychiatric nursing and 2+ years post-grad experience under a psychiatrist) can prescribe psychotropic controlled substances without the 7-day supply limit that applies to other NPs
• All APRNs must work under a protocol agreement with a supervising physician — Florida did not include psychiatric NPs in its recent independent practice law
• For treating minors with mental health conditions, the psychiatric nurse must have a consulting pediatrician or psychiatrist

Practice Implications:
Florida’s explicit allowance for psychiatric telehealth prescribing is a huge advantage. The out-of-state provider registration option makes it easier to serve Florida patients without the time and cost of full licensure.

PMHNPs can practice effectively, but you’ll need a supervising psychiatrist relationship documented. Think of it as similar to Texas, but at least NPs can prescribe stimulants with the right setup.

New York: Recently Aligned with Federal Flexibility

Telehealth Prescribing Rules:
Until mid-2025, New York had an old regulation that essentially mirrored the Ryan Haight Act. In May 2025, the state updated regulations to explicitly allow controlled substance prescribing via telehealth consistent with federal law.

This means as long as the DEA’s extension is in effect (through 2026), you can prescribe ADHD medications via telehealth in New York without state interference.

Key Requirements:

• PDMP: You must check the I-STOP/PMP registry before prescribing any Schedule II, III, or IV controlled substance — this is heavily enforced in NY
• E-Prescribing: Mandatory for all controlled substances since 2016 (New York was an early adopter)
• 90-Day Supply Option: New York allows up to a 90-day supply of stimulants for ADHD if the prescription indicates it’s for ADHD (using Code B) — useful for stable patients and reduces refill burden

NP Scope of Practice:
New York is progressive for NPs:

• After 3,600 hours of practice experience, PMHNPs can practice independently without a written collaborative agreement
• They must still maintain a ‘collaborative relationship’ with a physician (loosely defined), but no direct supervision required
• No quantity limits on NP prescribing of stimulants — they have the same authority as physicians for ADHD meds
• One-time CE requirement on pain management/addiction (more relevant for opioid prescribing)

Practice Implications:
New York’s 2025 regulatory update makes telehealth ADHD care straightforward. Experienced PMHNPs have essentially the same prescribing power as psychiatrists, which is rare.

The 90-day prescription option is a practice efficiency win — you can see stable ADHD patients quarterly instead of monthly.

New York is not part of IMLC, so out-of-state physicians need full licensure (no shortcuts).

Pennsylvania: Standard Federal Rules Apply, But NPs Are Limited

Telehealth Prescribing Rules:
Pennsylvania doesn’t have state-specific restrictions on telehealth prescribing of controlled substances beyond federal law. The state medical boards have confirmed that a valid patient-provider relationship can be established via telemedicine and prescribing is acceptable if standard of care is met.

During the federal PHE and extensions, PA providers could prescribe ADHD meds via telehealth. There’s no state law requiring an in-person exam.

Key Requirements:

• PDMP: Required to check PA PDMP before the first prescription of any controlled substance in a new course of treatment; many providers check every time to be safe
• E-Prescribing: Mandatory for controlled substances since 2019
• Standard of Care: Boards emphasize telehealth must meet the same standard as in-person — document thorough evaluations

NP Scope of Practice:
Pennsylvania is a restricted practice state:

• CRNPs must have a collaborative agreement with a physician to practice and prescribe
• For Schedule II controlled substances, NPs can prescribe up to a 30-day supply
• Any continuation beyond 30 days requires physician approval — the collaborating doctor must OK ongoing therapy
• Monthly chart review by the physician is expected for Schedule II prescribing

Practice Implications:
If you’re a PMHNP in Pennsylvania treating ADHD via telehealth, you’re legally limited to 30-day prescriptions. For ongoing patients on stable doses, you’ll need your supervising psychiatrist to review and approve monthly refills.

This creates workflow friction. Many Pennsylvania NP-led practices have the physician see the patient or at least review charts every 30 days to comply.

For psychiatrists, Pennsylvania is straightforward — full prescribing authority, and the state is part of IMLC (joined in 2022), making multi-state licensure easier.

Illinois: Two-Tier System for NPs

Telehealth Prescribing Rules:
Illinois permits telehealth prescribing of controlled substances with no state-imposed barriers beyond federal law. The state updated its Telehealth Act in 2021 to ensure parity and allow provider-patient relationships to be established via telehealth.

There’s no Illinois requirement for an in-person exam to prescribe stimulants.

Key Requirements:

• Illinois Controlled Substance License: In addition to your DEA registration, you need an Illinois CS license (state-level credential) to prescribe controlled substances in IL
• PDMP: The law requires documenting attempts to access the PMP for opioids and initial benzodiazepine prescriptions; checking for stimulants is encouraged but not explicitly mandated
• E-Prescribing: Required

NP Scope of Practice:
Illinois has a two-tier system for APRNs:

1. APRNs Under Collaboration:

• Must have a written collaborative agreement with a physician
• Can prescribe Schedule II for up to 30 days; any continuation requires physician approval
• The physician must review Schedule II prescribing monthly

2. Full Practice Authority (FPA) APRNs:

• After completing 4,000 hours of practice under collaboration + 250 hours of continuing education, APRNs can apply for FPA status
• FPA APRNs can practice and prescribe independently
• For Schedule II narcotic drugs (opioids) or benzodiazepines, they must maintain a ‘consultation relationship’ with a physician
• Critical distinction: Stimulants are Schedule II non-narcotic controlled substances, so the consultation requirement doesn’t apply to ADHD medications

What this means: An Illinois PMHNP with Full Practice Authority can prescribe Adderall independently via telehealth without physician oversight or monthly consults — because stimulants aren’t classified as ‘narcotic drugs’ under the consultation rule.

Practice Implications:
If you’re an experienced PMHNP with FPA credentials in Illinois, you have nearly the same autonomy as a psychiatrist for ADHD treatment.

If you’re a newer NP without FPA, you’re limited to 30-day prescriptions with physician approval for refills — similar to Pennsylvania.

Illinois also allows prescribing psychologists with training and physician collaboration, but they cannot prescribe Schedule II medications (including stimulants), so ADHD med management remains with MD/DOs and APRNs.

State Rules Summary Table

What This Means for Your Practice Economics

The Patient Acquisition Reality

Let’s talk money. If you’re considering DIY marketing to build an ADHD telehealth practice, understand the real costs:

SEO and Content Marketing:
Takes 6-12 months of consistent investment before you see meaningful patient flow. You’ll need to hire an agency or consultant ($2,000-5,000/month), create content, build backlinks, and wait. Most solo providers don’t have the expertise or budget for this.

Google Ads:
Mental health keywords are expensive — $15-40+ per click. Most clicks don’t convert to booked patients. Factor in:

• Ad spend testing and optimization
• Landing page development
• Lead nurturing (many don’t book immediately)
• No-show rates from cold leads

Realistic cost per booked patient through PPC: $200-400+ when you account for all costs.

Directory Listings:
Psychology Today, Zocdoc, and similar platforms charge monthly fees or per-booking fees. You’re competing with hundreds of other providers on the same page. Zocdoc charges $35-100+ per booking, plus monthly subscription fees.

The All-In Reality:
When you factor in agency fees, ad spend, staff time to handle and qualify leads, no-shows, failed campaigns, and months of investment before results, acquiring a qualified psychiatric patient through DIY channels typically costs $200-500+ per patient.

And that’s if you know what you’re doing.

The Platform Economics Model

This is where a platform like Klarity changes the equation. Instead of spending $3,000-5,000/month on marketing with uncertain results, you pay a standard listing fee per new patient lead.

The value props:

• No upfront marketing spend — zero monthly subscription fees or retainers
• Pre-qualified patients already matched to your specialty and availability
• No wasted ad spend on clicks that don’t convert
• Built-in telehealth infrastructure (no separate platform costs or IT headaches)
• Both insurance and cash-pay patient flow
• You control your schedule — only pay when you actually see patients

Think of it this way: instead of gambling $4,000/month on SEO and Google Ads hoping to get 10 new patients (which may or may not happen), you pay a predictable fee when a qualified patient books with you. That’s guaranteed ROI vs. marketing roulette.

For providers with prescribing restrictions (like PMHNPs in Texas or Pennsylvania), platforms can also provide physician collaboration infrastructure, which would cost $3,000-10,000/month to set up independently.

State-Specific Considerations

Your earning potential varies significantly by state due to scope of practice rules:

High-Autonomy States (CA, NY, IL with FPA):
PMHNPs can operate at full capacity, seeing patients and prescribing without physician bottlenecks. This means higher patient volume and better income potential.

Restricted States (TX, PA, IL without FPA):
NPs need physician involvement, which either:

1. Limits your earning potential (you can’t prescribe the most common ADHD meds in TX)
2. Requires you to split revenue with a collaborating physician
3. Creates workflow delays that reduce patient throughput

For platforms: This is why having both psychiatrists and PMHNPs in your provider network matters — you can serve patients in all states efficiently.

FAQ: What Providers Actually Ask

Can I prescribe ADHD medications via telehealth right now?

Yes, through December 31, 2026, under the federal extension. You must:

• Use live video (not just phone)
• Be licensed in the patient’s state
• Meet standard prescribing requirements (proper diagnosis, PDMP check, e-prescribing)
• Follow any state-specific rules (NP supervision requirements, etc.)

What happens in 2027 when the extension expires?

The DEA is finalizing permanent rules that will likely allow telehealth prescribing of controlled substances if you:

• Obtain a ‘Telemedicine Special Registration’ with the DEA
• Comply with enhanced safeguards (nationwide PDMP checks, identity verification)
• OR have seen the patient in person at least once

The goal is to maintain access while adding structure.

Do I need to see my ADHD patients in person eventually?

Not under current federal rules (through 2026). Some states may have practice guidelines suggesting periodic in-person visits for established patients, but there’s no federal mandate.

The upcoming DEA rules may require an in-person visit if you don’t obtain the special registration, or they may allow fully remote care indefinitely under the special reg pathway.

Can nurse practitioners prescribe Adderall via telehealth?

It depends on the state:

• Yes in: California (with supervision initially, independently by 2026), Florida (under physician protocol), New York (if experienced), Pennsylvania (30-day limit with physician approval), Illinois (30-day limit without FPA; unlimited with FPA)
• No in: Texas (APRNs barred from Schedule II prescribing in outpatient settings)

What’s the difference between treating ADHD vs. other psychiatric conditions via telehealth?

ADHD treatment typically involves Schedule II controlled substances (stimulants), which face tighter regulation than non-controlled psychiatric medications (like SSRIs for depression).

This means:

• More regulatory complexity (DEA rules, PDMP checks, e-prescribing requirements)
• Stricter scope of practice limitations for NPs in some states
• Higher scrutiny from regulators (the DEA has investigated telehealth companies for stimulant over-prescribing)

Treating depression or anxiety with non-controlled meds via telehealth is simpler from a regulatory standpoint.

How do PDMP checks work for telehealth?

Each state has a Prescription Drug Monitoring Program database showing a patient’s controlled substance prescription history. Most states require you to check it before prescribing:

• California: Before initial Rx and every 4 months
• Florida: Before each prescription for patients 16+
• New York: Before every Schedule II prescription
• Pennsylvania: Before first prescription in new treatment course
• Illinois: Recommended but not explicitly mandated for stimulants
• Texas: Recommended (mandatory for opioids/benzos but not stimulants)

You’ll need to register for your state’s PDMP portal. Some states have cross-state data sharing.

Can I treat patients in multiple states via telehealth?

Only if you’re licensed in each state where your patients are located. A patient’s physical location at the time of the appointment determines which state’s license you need.

Some options:

• IMLC (Interstate Medical Licensure Compact) for physicians makes it easier to get licenses in multiple states
• Florida’s out-of-state telehealth registration allows limited practice without full licensure
• Most states require full licensure (no shortcuts)

Plan on 2-6 months and $500-2,000+ per state for initial licensure.

What documentation do I need for telehealth ADHD prescribing?

Document the same elements as an in-person visit:

• Patient identity verification (confirm name, DOB, location)
• Clinical evaluation (ADHD diagnostic criteria, symptom assessment, functional impairment, rule-outs)
• PDMP check (document date and findings)
• Informed consent for telehealth and for controlled substance treatment
• Treatment plan and prescribing rationale
• Follow-up plan

Use your EHR’s telehealth encounter template and make it clear this was a video visit.

How does e-prescribing work for controlled substances?

You need an EPCS (Electronic Prescribing of Controlled Substances) system that meets DEA requirements:

• Two-factor authentication for the prescriber
• Audit trail
• Integration with pharmacy networks

Most telehealth platforms and EHRs (including Klarity’s infrastructure) have EPCS built in. You’ll need to complete identity proofing (one-time process verifying you are who you say you are).

Once set up, you electronically sign and send prescriptions to the patient’s pharmacy of choice.

What if a patient is traveling or moves to another state?

If they’re temporarily traveling: You can usually continue treating them via telehealth as long as you’re licensed in their home state and they’re not establishing permanent residence elsewhere. Document they’re traveling.

If they move permanently: You need a license in their new state to continue prescribing. Many providers will refer patients who move out of state rather than obtaining additional licenses for a single patient.

Why Join a Platform vs. Building Your Own Telehealth Practice

If you’re on the fence about joining a telehealth platform versus building your own practice, here’s the honest breakdown:

Build Your Own (DIY)

Pros:

• Full control over branding, scheduling, pricing
• Keep 100% of revenue (minus your overhead)
• Build long-term equity in your practice

Cons:

• Marketing costs $3,000-5,000+/month with 6-12 month ramp-up before ROI
• You need to handle: EHR setup, telehealth platform, EPCS technology, billing, credentialing with insurances (6-9 months), legal compliance, business entity setup
• Administrative time that’s not billable: managing leads, no-shows, appointment reminders, prescription refill requests
• Capital required: $10,000-30,000+ to launch properly
• Risk: No guaranteed patient volume

Realistic timeline to profitability: 12-18 months if you do everything right.

Join a Platform Like Klarity

Pros:

• Immediate patient flow — no marketing ramp-up period
• Zero upfront costs — pay only when you see patients
• Built-in infrastructure: EHR, telehealth platform, EPCS, patient communication, scheduling
• Credentialing support if you want to see insurance patients
• Compliance support for evolving regulations (like upcoming DEA rules)
• Flexible scheduling — work as much or as little as you want
• Predictable economics — you know your per-appointment cost upfront

Cons:

• Per-appointment fee — you’re paying for patient acquisition and infrastructure
• Less control over branding (you’re representing the platform)
• Platform sets some practice parameters

Realistic timeline to profitability: Immediate (you start seeing patients within weeks of joining).

The Math

Let’s say you want to see 40 new ADHD patients per month (plus follow-ups).

DIY approach:

• Marketing: $4,000/month
• EHR + telehealth platform: $500/month
• Business overhead (admin, accounting, etc.): $1,000/month
• Total monthly overhead: $5,500

If you see 40 new patients at an average reimbursement of $150 per appointment (insurance or cash), that’s $6,000 in revenue — $500 profit before paying yourself.

And that assumes you’ve already ramped up marketing and are hitting your patient targets consistently.

Platform approach:

• Let’s say the per-appointment listing fee is $100 (hypothetical — actual pricing varies)
• 40 new patients × $100 = $4,000 in fees
• Your revenue: 40 × $150 = $6,000
• Net: $2,000 after platform fees, before paying yourself

You’re netting 4x more and you didn’t spend 6 months building infrastructure or gambling on marketing.

For many providers, especially those starting out or scaling up, the platform model removes all the risk and lets you focus on clinical work instead of business development.

Next Steps: Getting Started with Telehealth ADHD Care

Whether you join a platform or build your own practice, here’s your action plan:

1. Verify Your Scope of Practice

Check your state’s rules:

• Can you prescribe stimulants as an NP in your state?
• Do you need physician collaboration? If so, how is that structured?
• What are the supply limits (if any)?

2. Get Licensed in Target States

If you want to treat patients in multiple states:

• Prioritize high-population states with favorable regulations (CA, NY, FL)
• Use IMLC if you’re a physician
• Budget 3-6 months for licensing

3. Register for PDMP Access

Sign up for PDMP access in every state where you’ll be prescribing. Most require a one-time registration.

4. Set Up EPCS

If building your own practice, choose an EHR with integrated EPCS and complete identity proofing. If joining a platform, confirm they provide this.

5. Understand the Economics

Calculate your per-patient revenue based on:

• Insurance reimbursement rates (if credentialed)
• Cash-pay rates (typically $150-300 for initial eval, $100-150 for follow-ups)
• Time per appointment (ADHD evals are typically 60 min; follow-ups 20-30 min)

6. Stay Current on Regulations

Bookmark:

• DEA announcements on telemedicine rules
• Your state medical board’s telehealth guidance
• PDMP rule changes

The regulatory landscape is evolving. What’s allowed in 2026 may require additional steps in 2027.

7. Consider Joining Klarity

If you want to skip the 12-month ramp-up, avoid $5,000/month marketing costs, and start seeing patients immediately:

Klarity Health provides:

• Pre-qualified ADHD patients matched to your availability
• Full telehealth infrastructure (EHR, video, EPCS)
• Both insurance and cash-pay patient flow
• Credentialing support
• Compliance updates as regulations evolve
• Flexible scheduling (set your own hours)

You focus on clinical care. We handle patient acquisition, technology, and administrative burden.

Learn more about joining Klarity’s provider network — we’re actively seeking psychiatrists and PMHNPs in all 50 states who want to treat ADHD via telehealth without the overhead of building a practice from scratch.

The Bottom Line

Yes, you can prescribe ADHD medications via telehealth in 2026 — but the rules are complex, state-dependent, and temporary. The current federal extension runs through December 2026, with permanent DEA rules coming in 2027 that will likely require enhanced compliance but still allow remote prescribing.

Your scope of practice varies dramatically by state. Psychiatrists have full authority everywhere. PMHNPs have near-full authority in some states (California, New York, Illinois with FPA) and significant restrictions in others (Texas, Pennsylvania).

The economics favor platforms for most providers. Instead of spending $3,000-5,000/month on uncertain marketing and 12-18 months building infrastructure, you can pay a predictable per-appointment fee and start seeing patients immediately with guaranteed ROI.

Whether you build your own practice or join a platform, the demand for ADHD telehealth care is massive and growing. Get your licensing and compliance framework right, understand your state’s rules, and you’ll be positioned to serve patients who desperately need accessible psychiatric care — while building a sustainable, flexible practice.

Sources and References

The following sources were consulted for the regulatory information in this guide:

1. DEA & HHS Press Release – Extension of Telemedicine Flexibilities Through 2026 (January 2, 2026) | HHS.gov and Healthcare Dive coverage | Official government announcement of fourth DEA extension

2. **DEA Press Release

Source:

• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,II%20to%20Schedule%20V%20drugs
• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,to%20hash%20out%20permanent%20regulations
• https://rxagent.co/blog/np-prescribing-authority#:~:text=Proposed%20DEA%20rules%20create%20a,for%20telemedicine%20prescribing
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://www.bon.texas.gov/faqpracticeaprn.asp.html#:~:text=there%20any%20settings%20other%20than,may%20prescribe%20Schedule%20II%20controlled
• https://www.ninthdistrict.org/home/2025/05/30/nysdoh-issues-guidance-on-prescribing-controlled-substances-via-telehealth#:~:text=as%20such%20terms%20are%20defined,the%20use%20of%20electronic%20prescribing
• https://www.pacodeandbulletin.gov/secure/pacode/data/049/chapter21/chap21toc.html#:~:text=,
• https://www.ilga.gov/agencies/JCAR/EntirePart?titlepart=06801300#:~:text=match%20at%20L5536%203,collaborating%20physician%20or%20podiatric%20physician
• https://rxagent.co/blog/np-prescribing-authority#:~:text=However%2C%20,3
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Prescribing%2C%20dispensing%2C%20or%20furnishing%20dangerous,the%20appropriate%20standard%20of%20care